Litman Gregory Wealth Management LLC Buys 997 Shares of Edwards Lifesciences Co. (NYSE:EW)

Litman Gregory Wealth Management LLC increased its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 0.8% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 126,447 shares of the medical research company’s stock after acquiring an additional 997 shares during the period. Edwards Lifesciences comprises approximately 0.9% of Litman Gregory Wealth Management LLC’s investment portfolio, making the stock its 25th largest holding. Litman Gregory Wealth Management LLC’s holdings in Edwards Lifesciences were worth $9,642,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of EW. Castleview Partners LLC bought a new stake in Edwards Lifesciences during the first quarter worth about $25,000. Compass Wealth Management LLC acquired a new position in Edwards Lifesciences during the fourth quarter worth approximately $31,000. Turtle Creek Wealth Advisors LLC acquired a new position in Edwards Lifesciences during the fourth quarter worth approximately $34,000. Jackson Grant Investment Advisers Inc. acquired a new position in Edwards Lifesciences during the third quarter worth approximately $38,000. Finally, Janiczek Wealth Management LLC increased its position in Edwards Lifesciences by 108.6% during the third quarter. Janiczek Wealth Management LLC now owns 582 shares of the medical research company’s stock worth $40,000 after buying an additional 303 shares during the last quarter. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Performance

Shares of NYSE:EW traded down $0.51 during mid-day trading on Friday, reaching $85.94. The company had a trading volume of 3,870,469 shares, compared to its average volume of 3,865,638. The company has a current ratio of 3.38, a quick ratio of 2.40 and a debt-to-equity ratio of 0.09. The firm has a market cap of $51.73 billion, a price-to-earnings ratio of 37.37, a PEG ratio of 4.32 and a beta of 1.05. The company’s 50-day moving average price is $90.15 and its 200-day moving average price is $78.31. Edwards Lifesciences Co. has a one year low of $60.57 and a one year high of $96.12.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Tuesday, February 6th. The medical research company reported $0.64 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.64. Edwards Lifesciences had a net margin of 23.35% and a return on equity of 23.56%. The business had revenue of $1.53 billion for the quarter, compared to analysts’ expectations of $1.50 billion. During the same quarter in the previous year, the firm posted $0.64 EPS. The business’s revenue for the quarter was up 13.3% compared to the same quarter last year. As a group, equities research analysts anticipate that Edwards Lifesciences Co. will post 2.76 EPS for the current fiscal year.

Insider Transactions at Edwards Lifesciences

In other news, VP Jean-Luc M. Lemercier sold 14,400 shares of the company’s stock in a transaction on Monday, April 8th. The shares were sold at an average price of $92.32, for a total value of $1,329,408.00. Following the transaction, the vice president now owns 173,849 shares of the company’s stock, valued at $16,049,739.68. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, VP Daniel J. Lippis sold 1,715 shares of the stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $90.98, for a total value of $156,030.70. Following the transaction, the vice president now owns 17,213 shares of the company’s stock, valued at $1,566,038.74. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, VP Jean-Luc M. Lemercier sold 14,400 shares of the stock in a transaction on Monday, April 8th. The shares were sold at an average price of $92.32, for a total value of $1,329,408.00. Following the completion of the transaction, the vice president now directly owns 173,849 shares in the company, valued at approximately $16,049,739.68. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 194,004 shares of company stock valued at $17,166,254. 1.29% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. OTR Global raised Edwards Lifesciences from a “mixed” rating to a “positive” rating in a research report on Tuesday, March 26th. Mizuho upped their target price on Edwards Lifesciences from $95.00 to $105.00 and gave the company a “buy” rating in a research report on Thursday, April 11th. Morgan Stanley upped their target price on Edwards Lifesciences from $95.00 to $103.00 and gave the company an “overweight” rating in a research report on Thursday, March 21st. Royal Bank of Canada upped their target price on Edwards Lifesciences from $95.00 to $101.00 and gave the company an “outperform” rating in a research report on Monday. Finally, Stifel Nicolaus upped their target price on Edwards Lifesciences from $70.00 to $83.00 and gave the company a “hold” rating in a research report on Wednesday, February 7th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $91.73.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.